Anthony Mancini - 16 Jun 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: Chief Global Commercialization Officer
Issuer ticker: RVMD
Reported as of: 16 Jun 2026
Net transaction value: -$720,490
SEC form: 4
Accepted by SEC: 18 Jun 2026, 16:11:23 UTC
Prior SEC filing: 28 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders, as Attorney-in-fact for Anthony Mancini

Key filing fact

Anthony Mancini filed Form 4 for Revolution Medicines, Inc. (RVMD) on 18 Jun 2026.

Key facts

This page summarizes Anthony Mancini's Form 4 filing for Revolution Medicines, Inc. (RVMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Jun 2026, 16:11.

Change

Previous filing in this sequence was filed on 28 May 2026.
Current net transaction value: -$720,490.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002124509 Primary reporting owner

Mancini Anthony

Relationship: Chief Global Commercialization Officer
Address: C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
Signature: /s/ Jack Anders, as Attorney-in-fact for Anthony Mancini
Signature date: 18 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Sale

Transaction value: $720,490
Shares: -4,615
Change %: -8.5%
Price: $156.12
Shares after: 49,975
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Pursuant to an automatic sell-to-cover, the shares were sold following the vesting of the restricted stock units solely to cover applicable withholding taxes.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F3

Includes 43,700 Restricted Stock Units.

Footnote F4

Includes 190 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

SEC remarks

Chief Global Commercialization Officer